Rationale and Evidence for Human Immunodeficiency Virus Treatment as Prevention at the Individual and Population Levels

Infectious Disease Clinics of North America

Volumn 28, Issue 4, 2014, Pages 549-561

  Hoffmann, Christopher J ^a   Gallant, Joel E ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Southwest CARE Center   (United States)

Author keywords

Adherence; Antiretroviral therapy; Epidemic; HIV; HIV testing; Prevention; TasP; Treatment as prevention

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; STAVUDINE; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ARTICLE; CD4 LYMPHOCYTE COUNT; DISEASE TRANSMISSION; DRUG SAFETY; DRUG TOLERABILITY; EPIDEMIC; HETEROSEXUAL FEMALE; HETEROSEXUAL MALE; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION RISK; MEDICAL DECISION MAKING; MEN WHO HAVE SEX WITH MEN; MORBIDITY; MORTALITY; NONHUMAN; POST EXPOSURE PROPHYLAXIS; PRACTICE GUIDELINE; RISK ASSESSMENT; RISK REDUCTION; UNPROTECTED SEX; VIRUS LOAD; VIRUS STRAIN; EVIDENCE BASED MEDICINE; FEMALE; HIV INFECTIONS; MALE; MASS SCREENING; PRE-EXPOSURE PROPHYLAXIS; TRANSMISSION; VIROLOGY;

ANTI-HIV AGENTS; EVIDENCE-BASED MEDICINE; FEMALE; HIV INFECTIONS; HUMANS; MALE; MASS SCREENING; PRE-EXPOSURE PROPHYLAXIS; VIRAL LOAD;

EID: 84913605288     PISSN: 08915520     EISSN: 15579824     Source Type: Journal    
DOI: 10.1016/j.idc.2014.08.003     Document Type: Review

References (62)

1. Joint United Nations Programme on HIV/AIDS Global report: UNAIDS report on the global AIDS epidemic 2013 2013, United Nations, Geneva (Switzerland).
2. Joint United Nations Programme on HIV/AIDS (UNAIDS) Getting to zero: HIV in eastern & southern Africa 2013, United Nations, Geneva (Switzerland).
3. Magnus M., Kuo I., Phillips G., et al. Elevated HIV prevalence despite lower rates of sexual risk behaviors among black men in the District of Columbia who have sex with men. AIDS Patient Care STDS 2010, 24:615-622.
4. Tanser F., de O.T., Maheu-Giroux M., et al. Concentrated HIV subepidemics in generalized epidemic settings. Curr Opin HIV AIDS 2014, 9:115-125.
5. Wolf R.C., Cheng A.S., Kapesa L., et al. Building the evidence base for urgent action: HIV epidemiology and innovative programming for men who have sex with men in sub-Saharan Africa. JInt AIDS Soc 2013, 16(Suppl 3):18903.
6. Beyrer C., Baral S.D., van Griensven F., et al. Global epidemiology of HIV infection in men who have sex with men. Lancet 2012, 380:367-377.
7. Nel A., Mabude Z., Smit J., et al. HIV incidence remains high in KwaZulu-Natal, South Africa: evidence from three districts. PLoS One 2012, 7:e35278.
8. Kilmarx P.H., Supawitkul S., Wankrairoj M., et al. Explosive spread and effective control of human immunodeficiency virus in northernmost Thailand: the epidemic in Chiang Rai province, 1988-99. AIDS 2000, 14:2731-2740.
9. Vlahov D., Junge B. The role of needle exchange programs in HIV prevention. Public Health Rep 1998, 113(Suppl 1):75-80.
10. Mnyani C.N., McIntyre J.A. Preventing mother-to-child transmission of HIV. BJOG 2009, 116(Suppl 1):71-76.
11. Townsend C.L., Cortina-Borja M., Peckham C.S., et al. Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000-2006. AIDS 2008, 22:973-981.
12. Motswere-Chirwa C., Voetsch A., Lu L., et al. Follow-Up of Infants Diagnosed with HIV - Early Infant Diagnosis Program, Francistown, Botswana, 2005-2012. MMWR Morb Mortal Wkly Rep 2014, 63:158-160.
13. Velasco-Hernandez J.X., Gershengorn H.B., Blower S.M. Could widespread use of combination antiretroviral therapy eradicate HIV epidemics?. Lancet Infect Dis 2002, 2:487-493.
14. Mofenson L.M., Lambert J.S., Stiehm E.R., et al. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 Team. NEngl J Med 1999, 341:385-393.
15. Quinn T.C., Wawer M.J., Sewankambo N., et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. NEngl J Med 2000, 342:921-929.
16. Attia S., Egger M., Muller M., et al. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS 2009, 23:1397-1404.
17. Powers K.A., Poole C., Pettifor A.E., et al. Rethinking the heterosexual infectivity of HIV-1: a systematic review and meta-analysis. Lancet Infect Dis 2008, 8:553-563.
18. Rodger A, Cambiano V, Vernazza P, et al. HIV transmission risk through condomless sex if the HIV+ partner is on suppressive ART. Conference on Retroviruses and Opportunistic Infections; Abstract 153LB. Boston, Massachusetts, March 3-6: 2014.
19. Pilcher C.D., Joaki G., Hoffman I.F., et al. Amplified transmission of HIV-1: comparison of HIV-1 concentrations in semen and blood during acute and chronic infection. AIDS 2007, 21:1723-1730.
20. Morrison C.S., Demers K., Kwok C., et al. Plasma and cervical viral loads among Ugandan and Zimbabwean women during acute and early HIV-1 infection. AIDS 2010, 24:573-582.
21. Sheth P.M., Kovacs C., Kemal K.S., et al. Persistent HIV RNA shedding in semen despite effective antiretroviral therapy. AIDS 2009, 23:2050-2054.
22. Baeten J.M., Kahle E., Lingappa J.R., et al. Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmission. Sci Transl Med 2011, 3:77ra29.
23. Cohen M.S., Chen Y.Q., McCauley M., et al. Prevention of HIV-1 infection with early antiretroviral therapy. NEngl J Med 2011, 365:493-505.
24. Vernazza P.L., Hirschel B., Bernasconi E., et al. Les personnes seropositives ne souffrant d'aucune autre MST et suivant un traitement antiretroviral efficace ne transmettent pas le VIH par voie sexuelle. Bull Med Suisse 2008, 89:165-169.
25. Benn P., Fisher M., Kulasegaram R. UK guideline for the use of post-exposure prophylaxis for HIV following sexual exposure (2011). Int J STD AIDS 2011, 22:695-708.
26. Centers for Disease Control and Prevention. Preventing new HIV infections. 2014. 2-20-2014. Available at: http://www.cdc.gov.
27. Granich R.M., Gilks C.F., Dye C., et al. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 2009, 373:48-57.
28. Hontelez J.A., Lurie M.N., Barnighausen T., et al. Elimination of HIV in South Africa through expanded access to antiretroviral therapy: a model comparison study. PLoS Med 2013, 10:e1001534.
29. Das M., Chu P.L., Santos G.M., et al. Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PLoS One 2010, 5:e11068.
30. Porco T.C., Martin J.N., Page-Shafer K.A., et al. Decline in HIV infectivity following the introduction of highly active antiretroviral therapy. AIDS 2004, 18:81-88.
31. Montaner J.S., Lima V.D., Harrigan P.R., et al. Expansion of HAART coverage is associated with sustained decreases in HIV/AIDS morbidity, mortality and HIV transmission: the "HIV treatment as prevention" experience in a Canadian setting. PLoS One 2014, 9:e87872.
32. Tanser F., Barnighausen T., Grapsa E., et al. High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal, South Africa. Science 2013, 339:966-971.
33. Iwuji C.C., Orne-Gliemann J., Tanser F., et al. Evaluation of the impact of immediate versus WHO recommendations-guided antiretroviral therapy initiation on HIV incidence: the ANRS 12249 TasP (Treatment as Prevention) trial in Hlabisa sub-district, KwaZulu-Natal, South Africa: study protocol for a cluster randomised controlled trial. Trial 2013, 14:230.
34. Vermund S.H., Fidler S.J., Ayles H., et al. Can combination prevention strategies reduce HIV transmission in generalized epidemic settings in Africa? The HPTN 071 (PopART) study plan in South Africa and Zambia. JAcquir Immune Defic Syndr 2013, 63(Suppl 2):S221-S227.
35. El-Sadr W.M., Lundgren J.D., Neaton J.D., et al. CD4+ count-guided interruption of antiretroviral treatment. NEngl J Med 2006, 355:2283-2296.
36. Severe P., Juste M.A., Ambroise A., et al. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. NEngl J Med 2010, 363:257-265.
37. Kitahata M.M., Gange S.J., Abraham A.G., et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. NEngl J Med 2009, 360:1815-1826.
38. Sterne J.A., May M., Costagliola D., et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 2009, 373:1352-1363.
39. Bell S.K., Little S.J., Rosenberg E.S. Clinical management of acute HIV infection: best practice remains unknown. JInfect Dis 2010, 202(Suppl 2):S278-S288.
40. Moir S., Buckner C.M., Ho J., et al. Bcells in early and chronic HIV infection: evidence for preservation of immune function associated with early initiation of antiretroviral therapy. Blood 2010, 116:5571-5579.
41. Fidler S., Fox J., Touloumi G., et al. Slower CD4 cell decline following cessation of a 3 month course of HAART in primary HIV infection: findings from an observational cohort. AIDS 2007, 21:1283-1291.
42. Laeyendecker O., Redd A.D., Lutalo T., et al. Frequency of long-term nonprogressors in HIV-1 seroconverters from Rakai Uganda. JAcquir Immune Defic Syndr 2009, 52:316-319.
43. Grabar S., Selinger-Leneman H., Abgrall S., et al. Prevalence and comparative characteristics of long-term nonprogressors and HIV controller patients in the French Hospital Database on HIV. AIDS 2009, 23:1163-1169.
44. Panel on Antiretroviral Guidelines for Adults and Adolescents Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents 2013, Department of Health and Human Services, Washington, DC, 10-30-2013.
45. Thompson M.A., Aberg J.A., Hoy J.F., et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 2012, 308:387-402.
46. Lundgren J.D., Clumeck N., Rockstroh J. Guidelines version 7.0 2013, European AIDS Clinical Society, Brussels (Belgium).
47. Williams I., Churchill D., Anderson J., et al. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012 (Updated November 2013. All changed text is cast in yellow highlight.). HIV Med 2014, 15(Suppl 1):1-85.
48. HIV/AIDS Programme Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach 2013, World Health Organization, Geneva (Switzerland).
49. Gallant J.E., Mehta S.H., Sugarman J. Universal antiretroviral therapy for HIV infection: should US treatment guidelines be applied to resource-limited settings?. Clin Infect Dis 2013, 57:884-887.
50. Chang L.W., Serwadda D., Quinn T.C., et al. Combination implementation for HIV prevention: moving from clinical trial evidence to population-level effects. Lancet Infect Dis 2013, 13:65-76.
51. Brenner B.G., Roger M., Routy J.P., et al. High rates of forward transmission events after acute/early HIV-1 infection. JInfect Dis 2007, 195:951-959.
52. Cohen M.S., Shaw G.M., McMichael A.J., et al. Acute HIV-1 Infection. NEngl J Med 2011, 364:1943-1954.
53. Brown A.E., Gill O.N., Delpech V.C. HIV treatment as prevention among men who have sex with men in the UK: is transmission controlled by universal access to HIV treatment and care?. HIV Med 2013, 14:563-570.
54. Koblin B.A., Mayer K.H., Eshleman S.H., et al. Correlates of HIV acquisition in a cohort of Black men who have sex with men in the United States: HIV prevention trials network (HPTN) 061. PLoS One 2013, 8:e70413.
55. Shisana O., Rehle T., Simbayi L., et al. South African national HIV prevalence, incidence, behaviour and communication survey 2008 2009, HSRC Press, Cape Town (South Africa).
56. Ministry of Health and Social Welfare Lesotho demographic and health survey 2009 2010, ICF Macro, Calverton (MD).
57. Moyer V.A. Screening for HIV: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2013, 159:51-60.
58. Branson B.M., Handsfield H.H., Lampe M.A., et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep 2006, 55:1-17.
59. Rosen S., Fox M.P. Retention in HIV care between testing and treatment in sub-Saharan Africa: a systematic review. PLoS Med 2011, 8:e1001056.
60. Gardner E.M., McLees M.P., Steiner J.F., et al. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis 2011, 52:793-800.
61. Thompson M.A., Mugavero M.J., Amico K.R., et al. Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS Care panel. Ann Intern Med 2012, 156:817-833. W.
62. Gupta R.K., Wainberg M.A., Brun-Vezinet F., et al. Oral antiretroviral drugs as public health tools for HIV prevention: global implications for adherence, drug resistance, and the success of HIV treatment programs. JInfect Dis 2013, 207(Suppl 2):S101-S106.